06/20/22 7:55 AMNasdaq : RXRX clinical trialRecursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF ConferenceIf successful, REC-2282 could be the first approved treatment for NF2 -mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S. Food and DrugRHEA-AIvery positive
06/02/22 7:55 AMNasdaq : RXRX conferencesRecursion to Participate in Upcoming Investor ConferencesRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:Jefferies Healthcare Conference — June 8 throughRHEA-AIneutral
05/10/22 4:29 PMNasdaq : RXRX earningsRecursion Provides Business Updates and Reports First Quarter 2022 Financial ResultsEnrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2 -mutated meningiomas in the second quarter 2022 Received Fast Track Designation for REC-4881, aRHEA-AIvery positive
05/02/22 7:55 AMNasdaq : RXRX conferencesRecursion to Participate in Upcoming Investor ConferenceRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conference:Bank of America 2022 Healthcare Conference — May 10RHEA-AIneutral
04/11/22 7:55 AMNasdaq : RXRX Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous PolyposisRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for theRHEA-AIvery positive
03/31/22 7:55 AMNasdaq : RXRX conferencesRecursion to Participate in Upcoming Investor ConferencesRecursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:Piper Sandler AI/Machine Learning Conference —RHEA-AIneutral
03/30/22 7:55 AMNasdaq : RXRX Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed CapitalAltitude Lab today announced its first cohort of startups raised $54M in seed funding while incubating at Altitude Lab. Founded by Recursion ® and theRHEA-AIneutral
03/24/22 7:55 AMNasdaq : RXRX Recursion Publishes First Environmental, Social and Governance (ESG) ReportReleases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity and philanthropy SALT LAKE CITY , March 24, 2022RHEA-AIvery positive
03/23/22 7:55 AMNasdaq : RXRX earningsRecursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial ResultsAnnounced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicines Expanded our collaboration with Bayer to include the use of Recursion's OS toRHEA-AIpositive
03/18/22 7:55 AMNasdaq : RXRX clinical trialRecursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous MalformationRecursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE CITY ,RHEA-AIneutral